Abstract. The cause of fibrotic disease is unknown. We have undertaken transcriptional profiling of dermal fibroblasts cultured from patients with the fibrotic disease scleroderma (systemic sclerosis, SSc) to identify genes overexpressed in fibrosis and have explored their contribution to the fibrotic phenotype. Connective tissue growth factor (CTGF, CCN2), a member of the CCN family of proteins, is overexpressed in SSc fibroblasts. In adult skin, CTGF is not normally expressed in dermal fibroblasts. However, CTGF is induced during the wound healing response and is constitutively overexpressed by fibroblasts present in fibrotic lesions. The overexpression of CTGF present in fibrotic lesions contributes to the phenotype of scleroderma in that CTGF promotes matrix deposition, and fibroblast adhesion and proliferation. In animal models, whereas either TGFb or CTGF alone produce only a transient fibrotic response, CTGF and TGFb act together to promote sustained fibrosis. Thus the constitutive overexpression of CTGF by fibroblasts present in fibrotic lesions would be expected to directly contribute to chronic, persistent fibrosis. 
Introduction
De novo synthesis of connective tissue occurs during the wound healing process. Normally this response is appropriately terminated; however, if the wound healing process occurs unabated, excessive deposition of extracellular matrix (ECM) occurs resulting in the formation of scar tissue.1 Excessive scarring results in the progressive, pathological scarring characteristic of fibrotic disease. One example of such a connective tissue disease is systemic sclerosis (scleroderma; SSc) which affects the skin as well as internal organs. 2, 3 There is no effective treatment for this disorder, in part because the etiology of this disease is unknown. Thus to identify appropriate targets for therapeutic intervention, it is necessary first to identify proteins overexpressed in fibrotic disease and then to assess the role that these proteins might have in the fibrotic phenotype.
CTGF is Overexpressed in Scleroderma Fibroblasts
By differential display and Western blot analyses, we found that connective tissue growth factor (CTGF, CCN2) is constitutively overexpressed in dermal fibroblasts isolated from SSc lesions. 4 In vitro, CTGF promotes fibroblast proliferation, matrix production, and granulation tissue formation.5 -7 CTGF also promotes cell adhesion and migration in a wide variety of cell types.8 Human foreskin fibroblasts adhere to CTGF through integrina6b1.8 In addition, a heparin-binding domain of CTGF, present in the carboxy-terminal region of CTGF, is important for CTGF-mediated fibroblast proliferation and adhesion.7,9 Therefore, CTGF promotes adhesion in a seemingly unique integrin-and HSPG-dependent fashion.
One of the most compelling pieces of evidence showing CTGF can independently induce matrix is that an expression vector encoding CTGF transfected into fibroblasts can activate a cotransfected reporter construct driven by the type I collagen promoter. 4 In vivo, CTGF acts with TGFb to induce a sustained fibrotic response, as although subcutaneous injection of TGFb into neonatal mice caused a transient fibrotic response and injection of CTGF alone had little effect, co-injection of CTGF and TGFb resulted in persistent fibrosis.10
CTGF Gene Regulation: CTGF Overexpression in Scleroderma Fibroblasts is Independent of Its TGFb
Response Element but Dependent on Sp1
CTGF is not normally expressed in skin unless induced, for example during the normal wound repair process.11 The profibrotic protein TGFb induces CTGF expression in dermal fibroblasts, but not in epidermal keratinocytes.6,11
-13 Although the TGFb induction of CTGF requires Smad3 and a functional Smad binding element in the CTGF promoter acting with a consensus TEF binding element ( Fig. 1) ,13,14 the elevated expression of the CTGF promoter in SSc fibroblasts seems to be independent of its Smad response element14 and TGFb response element.13 Instead, the elevated expression of the CTGF promoter in SSc fibroblasts requires a Sp1 binding element in the CTGF promoter, which is not required for the ability of CTGF to respond to TGFb (Fig. 2) .13,15 Sp1 regulates a wide variety of matrix genes16 suggesting that elevation of matrix genes in lesional SSc fibroblasts may be due to elevated Sp1 binding activity.
Hypothesis: CTGF and TGFb Act to Promote a Sustained Fibrotic Phenotype
Histological studies examining the distribution of CTGF and TGFb mRNAs in skin sections showed that in diffuse SSc lesions TGFb is overexpressed in the leading inflammatory edge of the lesion, but not in the lesional area itself.17 CTGF expression shows an expression pattern correlating with the severity of fibrosis; that is, CTGF expression is abundant in fibrotic lesions, even in the absence of markedly elevated amounts of TGFb ligand.18 Taken together, in contrast to the situation in normal dermal fibroblasts whereby CTGF is not normally expressed unless induced by TGFb through the TGFb response element, the persistent level of CTGF observed in lesional SSc fibroblasts seems to be independent of TGFb ligand. Based on these results, we hypothesize that in the normal wound healing response, the up-regulation of CTGF is dependent on the TGFb response element of the CTGF promoter, and is therefore subject to the controls that normally negatively regulate the TGFbinduced wound healing response. 19 In pathological fibrosis, however, fibroblasts display an elevated level of CTGF expression that is independent of the TGFb response element of the CTGF promoter.14,15 Thus we believe that, whereas TGFb is essential for the initiation of fibrosis, the persistent, TGFb-independent CTGF expression characteristic of fibrotic lesions perpetuates the fibrotic response.
Conclusion
The observations concerning CTGF expression and function have led to the intriguing notion that CTGF represents a novel, molecular target for therapeutic intervention in fibrotic disease.20 -23 As further research is conducted, the precise functional role of CTGF in cellular function as well as the mechanism of CTGF action should emerge. This process should result in the development of novel methods for anti-fibrotic intervention to prevent dermal scarring and alleviate the symptoms of fibrosis. 
